Chronic Thromboembolic Pulmonary Hypertension

被引:0
作者
Krittika Teerapuncharoen
Remzi Bag
机构
[1] University of Chicago,Division of Biological Sciences, Department of Medicine
[2] Mahidol University,Division of Respiratory Disease and Tuberculosis, Department of Medicine, Faculty of Medicine Siriraj Hospital
[3] University of Chicago,Section of Pulmonary and Critical Care, Department of Medicine
来源
Lung | 2022年 / 200卷
关键词
Chronic thromboembolic pulmonary hypertension; Chronic thromboembolic disease; Pulmonary embolism; Pulmonary arterial hypertension; Pulmonary thromboendarterectomy; Balloon pulmonary angioplasty;
D O I
暂无
中图分类号
学科分类号
摘要
Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.
引用
收藏
页码:283 / 299
页数:16
相关论文
共 907 条
  • [1] Simonneau G(2019)Haemodynamic definitions and updated clinical classification of pulmonary hypertension Eur Respir J 3 564-567
  • [2] Montani D(2021)ERS statement on chronic thromboembolic pulmonary hypertension Eur Respir J 129 978-985
  • [3] Celermajer DS(2006)Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism Proc Am Thorac Soc 10 4751-4763
  • [4] Denton CP(2017)An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan Eur Respir Rev 160 1822-1831
  • [5] Gatzoulis MA(2016)Monitoring for pulmonary hypertension following pulmonary embolism: the INFORM study Am J Med 124 1973-1981
  • [6] Krowka M(2018)Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies J Thorac Dis 15 395-399
  • [7] Williams PG(2017)Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature Eur Respir J 21 201-206
  • [8] Souza R(2017)Diagnosis of chronic thromboembolic pulmonary hypertension Eur Respir Rev 90 372-376
  • [9] Delcroix M(2021)Results from the United States chronic thromboembolic pulmonary hypertension registry: enrollment characteristics and 1-year follow-up Chest 173 1270-1275
  • [10] Torbicki A(2011)Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry Circulation 114 1929-1936